SynthesisPloS one2025
Prevalence of second mesiobuccal canal in maxillary molars of Iranian population: A systematic review with meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of the second mesiobuccal canal of maxillary molars in the South American population: a systematic review and meta-analysis of CBCT studies.Frontiers in dental medicine · 2026Pooled it
- Prevalence of second mesiobuccal canal in maxillary molars of Iranian population: A systematic review with meta-analysis.PloS one · 2025Pooled it
- Comparative diagnostic accuracy of ChatGPT in second mesiobuccal canal detection.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the main reasons for the failure of root canal treatment in maxillary molars is missing the second mesiobuccal (MB2) canal. This systematic review and meta-analysis aimed to estimate the prevalence of the MB2 canal in maxillary molars in the Iranian population.: Cross-sectional studies on the prevalence of MB2 canal in maxillary molars in the Iranian population were searched in PubMed, Scopus, Magiran, SID, IranMedex, and Google Scholar databases until 31 May 2024. The JBI Critical Appraisal Tool for prevalence studies was utilized for quality assessment. The prevalence of the MB2 canal was estimated with a 95% confidence coefficient (95%CI) using STATA18 software and the inverse variance method, separately for the first and second molars (CRD42024542862).In the present study, the prevalence of the MB2 canal in the maxillary first molar was 60% (95%CI, 53_67; I2 = 97.14%) and 33% (95%CI, 25_42; I2 = 97.42%) in the maxillary second molar. The highest prevalence rate of the MB2 canal in the maxillary first and second molars related to the microscope with 78% (95%CI, 54_101; I2 = 97.96%) and 61% (95%CI, 20_102%; I2 = 97.43%), respectively. The lowest prevalence rate of the MB2 canal in the maxillary first and second molars was related to the periapical radiograph with a rate of 15% (95%CI, -10_40; I2 = 91.17%) and 4% (95% CI, -8_17; I2 = 40.52%), respectively. The prevalence of the MB2 canal in the Iranian population in the first and second molars was 60% and 33%, respectively. This prevalence rate depended on the assessment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.